-

Medisca Acquires all IP assets of Maxima Pharmaceuticals Including the DIFFUSIMAX® Brand

MONTREAL--(BUSINESS WIRE)--On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.

“During this time of flux and uncertainty, our goal is to preserve and protect a product line that has had such a positive impact in shaping the compounding industry,” said Panagiota Danopoulos, Senior Vice President, Global Strategy & Innovation at Medisca.

Launched in 1997, DIFFUSIMAX® is a pioneer brand that has paved the way for PLO gels. Developed by a physician for physicians, DIFFUSIMAX® and DIFFUSIMAX®10 are the go-to topical vehicles for many providers across Canada. In use for 25 years and backed by dozens of stability studies for extended beyond-use dating, DIFFUSIMAX® is scientifically tried and tested with well-established brand equity.

“Striking this partnership with Medisca will create new possibilities for DIFFUSIMAX® by tapping into the inherent commercialization strengths of Medisca, while creating an opportunity for us to dedicate full efforts toward our passion in R&D, manufacturing, and consultative work,” said Dr. Kerry Siminoski, President of Maxima Pharmaceuticals.

DIFFUSIMAX® and DIFFUSIMAX®10 will continue to be manufactured in Edmonton, Alberta under the current Maxima leadership team and will be offered in both Pre-Mixed Cream and Compounding Kit formats. The brand will be available exclusively through major Canadian wholesalers. Medisca is also committed to developing additional resources to support providers, including access to formulas, stability study reports and more.

As a complement to the existing Medisca MediFlo™ PLO product line, the addition of DIFFUSIMAX® and DIFFUSIMAX®10 create a robust PLO gel portfolio designed to meet the diverse needs of compounding pharmacies across Canada.

For questions on these products, please contact the Medisca Compounding Services team at compoundingservices@medisca.com or at 1-800-665-6334 ext. 1203.

About MEDISCA®

Medisca is a global leader in healthcare with well-established footings in pharmaceutical compounding and advancements in scientific labs, cosmetics, other healthcare industries. For over 30 years, Medisca has been serving pharmacies and allied healthcare institutions with cutting-edge offerings and passionate commitment, developing a worldwide network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, convenient processes, and strategic global partnerships, Medisca provides top-quality and innovative products, industry-leading services, and world-class support systems. For more information visit www.medisca.ca and follow us on Twitter at @medisca.

Contacts

Gayle Padvaiskas
Vice President, Global Marketing
gpadvaiskas@medisca.com
1-800-665-6334

Medisca


Release Versions

Contacts

Gayle Padvaiskas
Vice President, Global Marketing
gpadvaiskas@medisca.com
1-800-665-6334

Social Media Profiles
More News From Medisca

Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876. The confidential settlement resolves the pending litigation. “This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachu...

Medisca Statement on Settlement With Department of Justice

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca Inc. has reached an agreement with the United States Department of Justice (DOJ) to resolve and terminate a civil investigation that began 9 years ago. The allegations made by the DOJ relate to the accuracy of the company’s disclosure of average wholesale prices (AWPs) for certain pharmaceutical ingredients from January 2012 to May 2015, and the reimbursement by the TRICARE program of pharmacies that purchased these ingredients at a price lower than t...

Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event was celebrated in the company of Medisca’s valued Plattsburgh team, business partners, and state and federal officials, including Congresswoman Elise Stefanik, Senator Dan Stec, and Assemblyman Billy Jones. "This event marks the completion of the largest project...
Back to Newsroom